Real-world impact of reminder packaging on antihypertensive treatment adherence and persistence

Patient Preference and Adherence

Volumn 6, Issue , 2012, Pages 499-507

  Dupclay, Leon ^a   Eaddy, Michael ^b   Jackson, James ^b   Raju, Aditya ^b   Shim, Andrew ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b XCENDA   (United States)

Author keywords

Adherence; Hypertension; Persistency; Reminder packaging

Indexed keywords

ANTIHYPERTENSIVE AGENT; HYDROCHLOROTHIAZIDE PLUS VALSARTAN;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG PACKAGING; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICATION POSSESSION RATIO; PATIENT ATTITUDE; PATIENT COMPLIANCE; PROPORTION OF DAYS COVERED; REMINDER PACKAGING; RETROSPECTIVE STUDY; SCORING SYSTEM; SURVIVAL RATE; TIME TO DISCONTINUATION; TIME TO REFILL;

EID: 84870660431     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S31417     Document Type: Article

References (35)

1. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens. 2004; 22(1):11-19.
2. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217-223.
3. Kochanek KD, Xu JQ, Murphy SL, et al. Deaths: preliminary data for 2009. Natl Vital Stat Rep. 2011;59(4):1-51.
4. Centers for Disease Control and Prevention. High Blood Pressure Fact Sheet. December, 2011. Available from: http://www.cdc.gov/DHDSP/data_statistics/fact_sheets/docs/fs_bloodpressure.pdf. Accessed May 8, 2012.
5. National Center for Health Statistics. Health, United States, 2010: With special feature on death and dying. Hyattsville, MD. 2011. Available from: http://www.cdc.gov/nchs/data/hus/hus10.pdf. Accessed May 8, 2012.
6. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012;125(1):188-197.
7. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003;290(2):199-206.
8. Golay A. Pharmacoeconomic aspects of poor adherence: can better adherence reduce healthcare costs? J Med Econ. 2011;14(5):594-608.
9. World Health Organization Report. Adherence to long-term therapies project. Evidence for action. Available from: http://whqlibdoc.who.int/publications/2003/9241545992.pdf. Accessed April 1, 2012.
10. Kulkarni SP, Alexander KP, Lytle B, Heiss G, Peterson ED. Long-term adherence with cardiovascular drug regimens. Am Heart J. 2006;151(1):185-191.
11. Monane M, Bohn RL, Gurwitz JH, et al. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am J Hypertens. 1997;10(7):697-704.
12. Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm. 2006;12(3):239-245.
13. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166(17):1836-1841.
14. Gadkari AS, McHorney CA. Unintentional non-adherence to chronic prescription medications: how unintentional is it really? BMC Health Serv Res. 2012;12(1):98.
15. Wilke T, Müller S, Morisky DE. Toward identifying the causes and combinations of causes increasing the risks of nonadherence to medical regimens: combined results of two German self-report surveys. Value Health. 2011;14(8):1092-1100.
16. Touchette D, Shipiro N. Medication compliance, adherence, and persistence: current status of behavioral and educational interventions to improve outcomes. J Manag Care Pharm. 2008;14(6):S2-S10.
17. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67-74.
18. Morisky, D. Adherence or compliance behavior. Encyclopedia of Public Health, 2002. Available from: http://www.enotes.com/adherence-compliance-behavior-reference/adherence-compliance-behavior. Accessed May 8, 2012.
19. Schneider PJ, Murphy JE, Pedersen CA. Impact of medication packaging on adherence and treatment outcomes in older ambulatory patients. J Am Pharm Assoc. 2008;48(1):58-63.
20. Zedler BK, Joyce A, Murrelle L, Kakad P, Harpe SE. A pharmacoepidemiologic analysis of the impact of calendar packaging on adherence to self-administered medications for long-term use. Clin Ther. 2011;33(5):581-597.
21. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992;45:197.
22. Dezii CM. Medication noncompliance: what is the problem? Manag Care. 2000;Suppl 9:7-12.
23. World Health Organization Report. Noncommunicable diseases and mental health adherence to long-term therapies project, 2003. Available from: http://whqlibdoc.who.int/publications/2003/9241545992.pdf. Accessed May 8, 2012.
24. Zedler BK, Kakad P, Colilla S, Murrelle L, Shah NR. Does packaging with a calendar feature improve adherence to self-administered medication for long-term use? A systematic review. Clin Ther. 2011; 33(1):62-73.
25. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA. 2006;296(21):2563-2571.
26. Mahtani KR, Heneghan CJ, Glasziou PP, Perera R. Reminder packaging for improving adherence to self-administered long-term medications. Cochrane Database Syst Rev. 2011;9:CD005025.
27. Fenerty SD, West C, Davis SA, et al. The effect of reminder systems on patients' adherence to treatment. Patient Prefer Adherence. 2012;6:127-135.
28. Granger BB, Bosworth HB. Medication adherence: emerging use of technology. Curr Opin Cardiol. 2011;26(4):279-287.
29. Ware GJ, Holford NH, Davison JG, Harris RG. Unit dose calendar packaging and elderly patient compliance. N Z Med J. 1991;104(924): 495-497.
30. Beckman A, Bernsten C, Parker MG, Thorslund M, Fastbom J. The difficulty of opening medicine containers in old age: a population-based study. Pharm World Sci. 2005;27(5):393-398.
31. Skaer TL, Sclar DA, Markowski DJ, Won JK. Effect of value-added utilities on prescription refill compliance and health care expenditures for hypertension. J Hum Hypertens. 1993;7(5):515-518.
32. Sclar DA, Skaer TL, Robison LM, et al. Effect of antihypertensive formulation on health service expenditures. Clin Auton Res. 1993;3(6): 363-368.
33. Chapman RH, Ferrufino CP, Kowal SL, et al. The cost and effectiveness of adherence-improving interventions for antihypertensive and lipid-lowering drugs. Int J Clin Pract. 2010;64(2):169-181.
34. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521-530.
35. Harpe SE. Using secondary data sources for pharmacoepidemiology and outcomes research. Pharmacotherapy. 2009;2992:138-153.